Norges Bank bought a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm boug
If you're interested in Amicus Therapeutics, Inc. (NASDAQ:FOLD), then you might want to consider its beta (a measure...
Bitcoin adoption, something that has somewhat stagnated after a burst of activity following bitcoin's epic 2017 rally, is about to get a boost from a surprising source—U.S. credit card giant Visa...
Geode Capital Management LLC raised its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 4.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange C
Amicus Therapeutics, Inc. (NASDAQ:FOLD) COO Bradley L. Campbell sold 2,500 shares of the business’s stock in a transaction dated Tuesday, April 7th. The shares were sold at an average price of $10.1
Bank of America Corp DE cut its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 69.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Co
On Thursday, April 9th, Fold unveiled the new Fold Card, which the company hailed as the "first bitcoin rewards card."
Alliancebernstein L.P. increased its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 66.0% during the fourth quarter, HoldingsChannel.com reports. The fund owned 531,503 shares of the
Payment gateway Visa has further divided into crypto by joining hands with Fold to offer a new co-branded card with spent rewards in Bitcoin.
Bitcoin rewards for dollars spent. That's the allure of a new Visa credit card from e-commerce startup Fold.
Franklin Resources Inc. decreased its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 49.2% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor
Amicus Therapeutics, Inc. (NASDAQ:FOLD) has received an average rating of “Buy” from the eight research firms that are covering the firm, MarketBeat reports. Two investment analysts have rated the
Nuveen Asset Management LLC lifted its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 92.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned
Amicus Therapeutics, Inc. (NASDAQ:FOLD) was the target of some unusual options trading activity on Monday. Investors acquired 703 call options on the company. This is an increase of approximately 813%
If you own shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) then it's worth thinking about how it contributes to the...
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE